(NASDAQ: CAI) Caris Life Sciences's forecast annual revenue growth rate of 21.61% is forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 8.64%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.42%.
Caris Life Sciences's revenue in 2026 is $812,033,000.On average, 12 Wall Street analysts forecast CAI's revenue for 2026 to be $287,383,777,623, with the lowest CAI revenue forecast at $276,928,320,620, and the highest CAI revenue forecast at $300,382,453,897. On average, 12 Wall Street analysts forecast CAI's revenue for 2027 to be $351,529,419,236, with the lowest CAI revenue forecast at $327,227,546,202, and the highest CAI revenue forecast at $382,895,790,245.
In 2028, CAI is forecast to generate $412,001,521,902 in revenue, with the lowest revenue forecast at $385,156,429,597 and the highest revenue forecast at $458,627,208,537.